skip to main contentskip to main menuskip to footer Universität Bielefeld Play Search
  • Organic Chemistry OC3 - Prof. Sewald

    © Universität Bielefeld

Welcome to the Organic and Bioorganic Chemistry work group!

ChemistryView highlights our findings on enzymatic bromination of proteins

ChemistryView highlights our findings on enzymatic halogenation of proteins at C-terminal tryptophan published in Angewandte Chemie. An engineered variant of the Trp 6-halogenase Thal allows post-translational bromination of a tetrapeptide tag with C-terminal tryptophan in proteins on a preparative scale using the brominating E. coli coexpression strain Brocoli. The bromoarene can be derivatized by palladium-catalyzed Suzuki–Miyaura cross-coupling at 37 °C. This opens new avenues for bio-orthogonal modification of proteins by biocatalytic bromination of minimally tagged proteins.

The article from ChemistryView can be found here.


Jörg Schwarzbich Inventor Award for new cancer drug

© Universität Bielefeld/Stefan Sättele

In recognition of his groundbreaking innovations, chemist Professor Dr. Norbert Sewald is awarded the Jörg Schwarzbich Inventor Award this year. This award honors his outstanding contributions to basic research in the field of cancer medications. The University Society Bielefeld (UGBi), in close collaboration with Bielefeld University, presents this honor, which comes with a prize of 40,000 euros. Norbert Sewald and his team have successfully developed a novel and highly potent drug that selectively targets tumor tissue, while affecting healthy cells to a significantly lesser extent. This approach enhances the effectiveness of the treatment while simultaneously improving its tolerability.

More information can be found here.


Interview with Hertz 87.9 about the Jörg Schwarzbich Inventor Award

In a conversation with Hertz 87.9, Norbert Sewald discusses his motivation in cancer research, the potential timeframe until the application of the new drug as a cancer medication in clinics, and the future plans for his research and his team.

The interview can be found here.


Surgery, radiation, and chemotherapy are the three main therapies used to treat cancerous tumors. The doctoral research network ‘Magicbullet::Reloaded’ is investigating another approach, with 15 doctoral researchers developing special molecules that stimulate the immune system to destroy tumor cells.

YaBiNaPA at Research_TV

When people in Cameroon suffer from malaria and other parasitic infectious diseases, they often cannot afford treatment – the imported synthetic medicines cost a lot of money. The graduate school YaBiNaPA of Bielefeld University and the University Yaoundé I in Cameroon aims to remedy this. research_tv presents the project.

Magicbullet at Research_TV

How do active substances have to be structured in order to target cancer cells selectively? Fifteen doctoral students in the “Magicbullet” network have spent three years conducting research into this.

Newest Publication

back to top